S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
LON:HIK

Hikma Pharmaceuticals (HIK) Share Price, News & Analysis

GBX 1,918.50
+38.00 (+2.02%)
(As of 03/28/2024 ET)
Today's Range
1,887.50
1,937.50
50-Day Range
1,841
2,083
52-Week Range
1,614.50
2,222
Volume
332,600 shs
Average Volume
443,218 shs
Market Capitalization
£4.26 billion
P/E Ratio
2,863.43
Dividend Yield
2.97%
Price Target
GBX 2,018.75

Hikma Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
5.2% Upside
GBX 2,018.75 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
0.80mentions of Hikma Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.60 out of 5 stars

HIK stock logo

About Hikma Pharmaceuticals Stock (LON:HIK)

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms in North America, the Middle East, North Africa, and Europe. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company was founded in 1978 and is headquartered in London, the United Kingdom.

HIK Stock Price History

HIK Stock News Headlines

[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
FTSE 100 Closes Up 0.12% Ahead of U.K. Jobs Data
Hikma beats profit estimates thanks to narcolepsy drug
Hikma Pharmaceutical FY EPS 85c
See More Headlines
Receive HIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 5/3 Dividend
3/21/2024
Today
3/28/2024
Dividend Payable
5/03/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
9,100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 2,018.75
High Stock Price Target
GBX 2,150
Low Stock Price Target
GBX 1,800
Potential Upside/Downside
+5.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
£190 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£2.88 billion
Cash Flow
GBX 230.07 per share
Book Value
GBX 996 per share

Miscellaneous

Free Float
N/A
Market Cap
£4.26 billion
Optionable
Not Optionable
Beta
0.45
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Engineer Said Samih Taleb Darwazah (Age 67)
    Executive Chairman
    Comp: $2.33M
  • Mr. Mazen Samih Taleb Darwazah (Age 66)
    Executive Vice Chairman & President of MENA
    Comp: $1.53M
  • Mr. Riad Mishlawi
    CEO & Director
  • Mr. Khalid Waleed Hosny Al Nabilsi (Age 52)
    Chief Financial Officer
  • Mr. Guy Featherstone
    Associate Director of Investor Relations
  • Mr. Bassam Wael Rushdi Kanaan CFA (Age 59)
    CPA, Executive VP of Corporate Development and M&A
  • Mr. Hussein Omar Arkhagha
    Chief People Officer
  • Ms. Susan Ringdal
    Executive VP of Strategic Planning & Global Affairs
  • Mr. Brian Hoffmann
    President of Generics
  • Mr. Samuel Park
    Global Head of Intellectual Property (IP) & General Counsel for US

HIK Stock Analysis - Frequently Asked Questions

Should I buy or sell Hikma Pharmaceuticals stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HIK shares.
View HIK analyst ratings
or view top-rated stocks.

What is Hikma Pharmaceuticals' stock price target for 2024?

6 brokerages have issued 12 month target prices for Hikma Pharmaceuticals' stock. Their HIK share price targets range from GBX 1,800 to GBX 2,150. On average, they predict the company's share price to reach GBX 2,018.75 in the next twelve months. This suggests a possible upside of 5.2% from the stock's current price.
View analysts price targets for HIK
or view top-rated stocks among Wall Street analysts.

How have HIK shares performed in 2024?

Hikma Pharmaceuticals' stock was trading at GBX 1,789 at the start of the year. Since then, HIK stock has increased by 7.2% and is now trading at GBX 1,918.50.
View the best growth stocks for 2024 here
.

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals declared a dividend on Thursday, February 22nd. Stockholders of record on Thursday, March 21st will be given a dividend of GBX 0.47 per share on Friday, May 3rd. This represents a yield of 1.86%. The ex-dividend date of this dividend is Thursday, March 21st. This is a boost from the stock's previous dividend of GBX 0.25. The official announcement can be seen at this link.
Read our dividend analysis for HIK
.

Is Hikma Pharmaceuticals a good dividend stock?

Hikma Pharmaceuticals (LON:HIK) pays an annual dividend of GBX 57 per share and currently has a dividend yield of 2.93%. The dividend payout ratio is 8,507.46%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for HIK.

What other stocks do shareholders of Hikma Pharmaceuticals own?
How do I buy shares of Hikma Pharmaceuticals?

Shares of HIK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:HIK) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners